Avestar Capital’s Neurocrine Biosciences NBIX Stock Holding History

Avestar Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,165	Closed	-$219K	–	276
2020 Q3	$219K	Buy	+2,165	New	+$250K	0.07%	203

Other funds holding NBIX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Avestar Capital's NBIX Position: Q4 2020 in Review

Avestar Capital sold out of Neurocrine Biosciences (NBIX) in Q4 2020, closing a stake of 2,165 shares — an estimated $219K sold.

Avestar Capital first reported a position in NBIX in Q3 2020 and held it in 1 quarter. The position peaked at $219K in Q3 2020. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2020.

Avestar Capital reported no remaining Neurocrine Biosciences position as of Q4 2020 after selling out during the quarter.
Avestar Capital sold 2,165 Neurocrine Biosciences shares in Q4 2020, an estimated $219K.
Avestar Capital first reported a position in Neurocrine Biosciences in Q3 2020 and held it in 1 quarter.
Avestar Capital's Neurocrine Biosciences position peaked at $219K in Q3 2020.
405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2020.

Based on Avestar Capital's 13F filing for Q4 2020, filed 1 Feb 2021.